
zzso zzso oral administration of zzso may present a theoretical advantage over intravenous administration of the zzso This phase I trial was carried out to determine the recommended duration of oral zzso in combination with a fixed dose of zzso zzso patients with varied solid tumors, who were not candidates for standard chemotherapy, were administered an escalating duration zzso 9 or 12 consecutive zzso of oral zzso (a zzso capsule three times zzso combined with zzso zzso administered on day 1, by a zzso zzso intravenous infusion, to define the maximum tolerated dose on the basis of the acute zzso that were zzso zzso was started on day 2; the cycles repeated every 28 days until disease progression or zzso zzso was carried out during the two first zzso The maximum tolerated dose was determined to be the zzso treatment level, with two cases of grade 4 zzso grade 3 anemia and zzso As no severe toxicity occurred with the zzso treatment level and in an attempt to explore an optimal zzso a new 10-day treatment plan was studied in three zzso As one patient presented zzso toxicity at that level, five additional patients were included to establish the recommended zzso zzso zzso among all patients were moderate, consisting of grade 2 zzso and zzso No zzso death zzso zzso responses were observed in four patients and stabilization in three zzso zzso highlighted no interaction between zzso and zzso zzso oral zzso zzso for 10 days in combination with zzso zzso 5 presents acceptable toxicity and zzso The main toxicity remains zzso 

